• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

概述严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其主要变体的特征:现状与未来发展路径

Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.

作者信息

Ortega Miguel A, García-Montero Cielo, Fraile-Martinez Oscar, Colet Paolo, Baizhaxynova Ardak, Mukhtarova Kymbat, Alvarez-Mon Melchor, Kanatova Kaznagul, Asúnsolo Angel, Sarría-Santamera Antonio

机构信息

Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.

Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.

出版信息

J Pers Med. 2022 Jun 18;12(6):995. doi: 10.3390/jpm12060995.

DOI:10.3390/jpm12060995
PMID:35743779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9225183/
Abstract

Over the two years that we have been experiencing the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, our challenges have been the race to develop vaccines and the difficulties in fighting against new variants due to the rapid ability of the virus to evolve. In this sense, different organizations have identified and classified the different variants that have been emerging, distinguishing between variants of concern (VOC), variants of interest (VOI), or variants under monitoring (VUM). The following review aims to describe the latest updates focusing on VOC and already de-escalated variants, as well as to describe the impact these have had on the global situation. Understanding the intrinsic properties of SARS-CoV-2 and its interaction with the immune system and vaccination is essential to make out the underlying mechanisms that have led to the appearance of these variants, helping to determine the next steps for better public management of this pandemic.

摘要

在我们经历严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行的这两年里,我们面临的挑战包括竞相研发疫苗以及由于病毒快速进化能力而在对抗新变种方面遇到的困难。从这个意义上说,不同组织已经识别并分类了不断出现的不同变种,区分了关注变种(VOC)、感兴趣变种(VOI)或监测中的变种(VUM)。以下综述旨在描述聚焦于VOC和已降级变种的最新进展,以及描述这些变种对全球形势产生的影响。了解SARS-CoV-2的内在特性及其与免疫系统和疫苗接种的相互作用,对于弄清楚导致这些变种出现的潜在机制至关重要,有助于确定更好地进行这场大流行公共管理的下一步措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce8e/9225183/c4b2c8da4399/jpm-12-00995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce8e/9225183/7db726df649a/jpm-12-00995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce8e/9225183/c4b2c8da4399/jpm-12-00995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce8e/9225183/7db726df649a/jpm-12-00995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce8e/9225183/c4b2c8da4399/jpm-12-00995-g002.jpg

相似文献

1
Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.概述严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其主要变体的特征:现状与未来发展路径
J Pers Med. 2022 Jun 18;12(6):995. doi: 10.3390/jpm12060995.
2
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
3
SARS-CoV-2 Variants of Concern.关注的 SARS-CoV-2 变体。
Yonsei Med J. 2021 Nov;62(11):961-968. doi: 10.3349/ymj.2021.62.11.961.
4
Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing.使用扩增子下一代测序鉴定 SARS-CoV-2 关注变体。
Microbiol Spectr. 2022 Aug 31;10(4):e0073622. doi: 10.1128/spectrum.00736-22. Epub 2022 Jun 27.
5
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
6
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.宿主对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的保护性免疫与 COVID-19 疫苗诱导的对 SARS-CoV-2 及其变体的免疫。
Viruses. 2022 Nov 17;14(11):2541. doi: 10.3390/v14112541.
7
Epidemiological analysis of the emergence and disappearance of the SARS-CoV-2 Kappa variant within a region of British Columbia, Canada.加拿大不列颠哥伦比亚省某地区严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)卡帕变种出现与消失的流行病学分析。
Can Commun Dis Rep. 2022 Jan 26;48(1):22-26. doi: 10.14745/ccdr.v48i01a04.
8
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.新型 SARS-CoV-2 变异株的进化、传播模式和突变特征。
mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21.
9
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突变及其对诊断、治疗和疫苗的影响。
Front Med (Lausanne). 2022 Feb 22;9:815389. doi: 10.3389/fmed.2022.815389. eCollection 2022.
10
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.卫星五号疫苗接种后的纵向研究显示,随着时间的推移,SARS-CoV-2 中和抗体具有持久性,并且对病毒变异的中和逃逸能力降低。
mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25.

引用本文的文献

1
Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months.6个月后老年人对SARS-CoV-2感染的免疫反应降低。
Front Immunol. 2025 May 9;16:1596065. doi: 10.3389/fimmu.2025.1596065. eCollection 2025.
2
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.抗 SARS-CoV-2 治疗药物的研发进展。
Int J Mol Sci. 2024 Oct 9;25(19):10820. doi: 10.3390/ijms251910820.
3
COVID-19 mutations: An overview.新型冠状病毒肺炎突变:概述

本文引用的文献

1
Fourth dose of COVID-19 vaccine: Does it still contribute any additional immunoprotection?新冠病毒疫苗第四剂:它是否仍能提供额外的免疫保护?
J Taibah Univ Med Sci. 2022 Jun;17(3):533-536. doi: 10.1016/j.jtumed.2022.04.004. Epub 2022 Apr 30.
2
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.加强针对 SARS-CoV-2 奥密克戎变异株的 COVID-19 疫苗接种:系统评价。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2062983. doi: 10.1080/21645515.2022.2062983. Epub 2022 May 2.
3
Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent.
World J Methodol. 2024 Sep 20;14(3):89761. doi: 10.5662/wjm.v14.i3.89761.
4
Analysis of SARS-CoV-2 genome evolutionary patterns.分析 SARS-CoV-2 基因组的进化模式。
Microbiol Spectr. 2024 Feb 6;12(2):e0265423. doi: 10.1128/spectrum.02654-23. Epub 2024 Jan 10.
5
Prognosis Predictive Markers in Patients with Chronic Obstructive Pulmonary Disease and COVID-19.慢性阻塞性肺疾病合并新型冠状病毒肺炎患者的预后预测标志物
Diagnostics (Basel). 2023 Aug 4;13(15):2597. doi: 10.3390/diagnostics13152597.
6
Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform.在印度,对野生型(B.1)病毒、Kappa(B.1.617.1)和 Delta(B.1.617.2)变体以及 COVISHIELD 疫苗免疫的自然感染中,针对 10 种 SARS-CoV-2 变体的可变中和抗体反应:MSD 平台的实用性。
Front Immunol. 2023 Jun 5;14:1181991. doi: 10.3389/fimmu.2023.1181991. eCollection 2023.
7
Recent Developments in Electrochemical-Impedimetric Biosensors for Virus Detection.电化学阻抗生物传感器在病毒检测中的最新进展。
Int J Mol Sci. 2022 Dec 14;23(24):15922. doi: 10.3390/ijms232415922.
8
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗:一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
循环中的新冠病毒变异株对疫苗接种者或康复者血清的中和异质性。
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0100. Epub 2022 Apr 26.
4
SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022.严重急性呼吸综合征冠状病毒2型奥密克戎亚谱系BA.2取代BA.1.1:2021年9月至2022年3月日本的基因组监测
J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.040. Epub 2022 Apr 29.
5
Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1.1在仓鼠中的致病性。
EBioMedicine. 2022 Jun;80:104035. doi: 10.1016/j.ebiom.2022.104035. Epub 2022 Apr 28.
6
Emergence of Two Distinct SARS-CoV-2 Gamma Variants and the Rapid Spread of P.1-like-II SARS-CoV-2 during the Second Wave of COVID-19 in Santa Catarina, Southern Brazil.巴西南里奥格兰德州圣卡塔琳娜州第二波 COVID-19 期间两种不同 SARS-CoV-2 伽马变异株的出现和 P.1 样-II SARS-CoV-2 的快速传播。
Viruses. 2022 Mar 27;14(4):695. doi: 10.3390/v14040695.
7
The "Wolf" Is Indeed Coming: Recombinant "Deltacron" SARS-CoV-2 Detected.“狼”真的来了:检测到重组“德尔塔克戎”新冠病毒。
China CDC Wkly. 2022 Apr 8;4(14):285-287. doi: 10.46234/ccdcw2022.054.
8
Are new Omicron subvariants a threat? Here's how scientists are keeping watch.新型奥密克戎亚变体构成威胁吗?以下是科学家的监测方式。
Nature. 2022 Apr;604(7907):605-606. doi: 10.1038/d41586-022-01069-4.
9
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.在全国范围内接种第四剂 BNT162b2 mRNA 新冠疫苗。
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
10
Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity.根据疾病严重程度,COVID-19 后 1 年的免疫反应不同。
Front Immunol. 2022 Mar 21;13:830433. doi: 10.3389/fimmu.2022.830433. eCollection 2022.